Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 5/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.55 |
| ▸ | CDC25B | P30305 | 5/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.55 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710949 | 1.00 | PTPN2 (0.55) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL28022277 | 0.85 | NOS2 (0.57) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL1711214 | 0.85 | NOS2 (0.57) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL1711462 | 0.85 | NOS3 (0.57) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL1710894 | 0.85 | PTPN2 (0.53) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL1711216 | 0.85 | NOS2 (0.57) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL1711460 | 0.85 | NOS3 (0.57) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL1710892 | 0.85 | PTPN2 (0.53) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| SCHEMBL1711509 | 0.83 | PTPN2 (0.51) | PTPN2PTPN1CDC25BPTPN6NOS2 | |
| Hydrochloric Acid SCHEMBL1711409 | 0.83 | PTPN2 (0.51) | PTPN2PTPN1CDC25BPTPN6NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150510-B2 | Amino acid derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2345635-A1 | AMINO ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172442-A1 | AMINO ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172442-A1 | AMINO ACID DERIVATIVE | OPRL1, OPRK1, SLC1A1 | PTPN2 3704/4885PTPN1 4062/4885CDC25B 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.